ICU Girisim Sermayesi Yatirim Ortakligi A.S. logo

ICU Girisim Skips Dividend Following 198 Million Lira Loss

ICU Girisim has decided to propose not distributing dividends to its general assembly following a net period loss of 198.49 million lira in the 2025 fiscal period.
Yatırım Masası1 min read

ICU Girisim Sermayesi Yatirim Ortakligi (ICUGS) announced that it will not distribute dividends for the 2025 fiscal period, which concluded with a consolidated net period loss of 198.49 million lira (TRY). The company's board of directors proposed that the net loss of 290.84 million lira, realized according to Tax Procedure Law records, be transferred to the prior years' profits and losses account.

Will ICU Girisim distribute dividends?

According to the dividend distribution table published on KAP (Public Disclosure Platform), no dividend will be paid to shareholders in the form of cash or a bonus share issue, as there is no distributable profit under the legislation. The proposal not to pay dividends, covering all Group A and B shares, will be submitted for shareholder approval at the ordinary general assembly meeting to be held on November 19, 2026.

What is the latest status of ICUGS shares?

Shares of the company, which also announced a new board member appointment on the same day, traded under selling pressure during the session. ICUGS completed the day down 2.61% at 1.12 lira, while trading volume was recorded at 36.72 million. Having fluctuated between 1.08 lira and 6.89 lira in the past 1 year, the stock is trading just above its 52-week low band.

This content is for information purposes only and does not constitute investment advice.

Add Yatırım Masası as a preferred source on Google
This article is a translation of the original Turkish version published by Yatırım Masası. Read the original in Turkish
Prepared by the Yatırım Masası newsroom from current market developments and official data.
This is not investment advice. The data and commentary in this article are for information only; make investment decisions based on your own research and, where needed, advice from a licensed professional.

Latest news